|
KMID : 0942820050040010032
|
|
Journal of Korean Brain Tumor Society
2005 Volume.4 No. 1 p.32 ~ p.37
|
|
|
An Early Clinical Experience of Temozolomide Chemotherapy in Glioma
|
|
Won Gun-Woo
Cho Do-Sang
Chung Yong-Gu
Kim Han-Kyeom
Kim Chul-Yong
|
|
|
Abstract
|
|
|
Objective: A novel second-generation alkylating agent, temozolomide(TMZ), has recently demonstrated efficacy and safety in patients with glioma. The authors describe preliminary experience using TMZ for the treatment of patients with recurrent or remnant gliomas, who had previously undergone surgery with radiotherapy and chemotherapy.
Methods: From August 2001 to September 2002, patients with recurrent or remnant glioma were recruited for the study. All patients had received surgery and adjuvant radiotherapy with conventional chemotherapy. TMZ was administered at 200mg/m2 once daily for 5days every 28days. Response was evaluated by brain MRI six months later.
Results: A total 10patients with a mean age of 41.2years were enrolled in the study. Two patients died during the followup period because of sepsis rather than progressive disease. All but these two cases were still on treatment and a mean of 6.3TMZ treatment cycles were administered. Two of these patients responded to TMZ chemotherapy；follow-up MR images revealed more than a 50% decrease in tumor mass, especially of the enhancing lesion. Treatment was in general well tolerated. Significant hematologic adverse events were not reported.
Conclusion: Despite the short duration of follow-up period and small patients group, this study demonstrates satisfactory results for the efficacy of TMZ in glioma. Nevertheless, there is a need for further randomized controlled trials to fully define the use of this new drug.
|
|
|
KEYWORD
|
|
|
Temozolomide, Glioma
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|